These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 20530712

  • 1. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design.
    Wei P, Walls M, Qiu M, Ding R, Denlinger RH, Wong A, Tsaparikos K, Jani JP, Hosea N, Sands M, Randolph S, Smeal T.
    Mol Cancer Ther; 2010 Jun; 9(6):1618-28. PubMed ID: 20530712
    [Abstract] [Full Text] [Related]

  • 2. Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer models.
    Zhang CC, Pavlicek A, Zhang Q, Lira ME, Painter CL, Yan Z, Zheng X, Lee NV, Ozeck M, Qiu M, Zong Q, Lappin PB, Wong A, Rejto PA, Smeal T, Christensen JG.
    Clin Cancer Res; 2012 Sep 15; 18(18):5008-19. PubMed ID: 22806875
    [Abstract] [Full Text] [Related]

  • 3. Preclinical analysis of the γ-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia.
    Samon JB, Castillo-Martin M, Hadler M, Ambesi-Impiobato A, Paietta E, Racevskis J, Wiernik PH, Rowe JM, Jakubczak J, Randolph S, Cordon-Cardo C, Ferrando AA.
    Mol Cancer Ther; 2012 Jul 15; 11(7):1565-75. PubMed ID: 22504949
    [Abstract] [Full Text] [Related]

  • 4. Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model.
    Arcaroli JJ, Quackenbush KS, Purkey A, Powell RW, Pitts TM, Bagby S, Tan AC, Cross B, McPhillips K, Song EK, Tai WM, Winn RA, Bikkavilli K, Vanscoyk M, Eckhardt SG, Messersmith WA.
    Br J Cancer; 2013 Aug 06; 109(3):667-75. PubMed ID: 23868008
    [Abstract] [Full Text] [Related]

  • 5. GSI-I (Z-LLNle-CHO) inhibits γ-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia.
    Meng X, Matlawska-Wasowska K, Girodon F, Mazel T, Willman CL, Atlas S, Chen IM, Harvey RC, Hunger SP, Ness SA, Winter SS, Wilson BS.
    Leukemia; 2011 Jul 06; 25(7):1135-46. PubMed ID: 21494254
    [Abstract] [Full Text] [Related]

  • 6. A novel triazole, NMK-T-057, induces autophagic cell death in breast cancer cells by inhibiting γ-secretase-mediated activation of Notch signaling.
    Das A, Narayanam MK, Paul S, Mukhnerjee P, Ghosh S, Dastidar DG, Chakrabarty S, Ganguli A, Basu B, Pal M, Chatterji U, Banerjee SK, Karmakar P, Kumar D, Chakrabarti G.
    J Biol Chem; 2019 Apr 26; 294(17):6733-6750. PubMed ID: 30824542
    [Abstract] [Full Text] [Related]

  • 7. PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.
    Wang K, Zhang Q, Li D, Ching K, Zhang C, Zheng X, Ozeck M, Shi S, Li X, Wang H, Rejto P, Christensen J, Olson P.
    Clin Cancer Res; 2015 Mar 15; 21(6):1487-96. PubMed ID: 25564152
    [Abstract] [Full Text] [Related]

  • 8. Synergistic effect of the γ-secretase inhibitor PF-03084014 and docetaxel in breast cancer models.
    Zhang CC, Yan Z, Zong Q, Fang DD, Painter C, Zhang Q, Chen E, Lira ME, John-Baptiste A, Christensen JG.
    Stem Cells Transl Med; 2013 Mar 15; 2(3):233-42. PubMed ID: 23408105
    [Abstract] [Full Text] [Related]

  • 9. Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer.
    Cui D, Dai J, Keller JM, Mizokami A, Xia S, Keller ET.
    Clin Cancer Res; 2015 Oct 15; 21(20):4619-29. PubMed ID: 26202948
    [Abstract] [Full Text] [Related]

  • 10. A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014.
    Messersmith WA, Shapiro GI, Cleary JM, Jimeno A, Dasari A, Huang B, Shaik MN, Cesari R, Zheng X, Reynolds JM, English PA, McLachlan KR, Kern KA, LoRusso PM.
    Clin Cancer Res; 2015 Jan 01; 21(1):60-7. PubMed ID: 25231399
    [Abstract] [Full Text] [Related]

  • 11. Notch Inhibitor PF-03084014 Inhibits Hepatocellular Carcinoma Growth and Metastasis via Suppression of Cancer Stemness due to Reduced Activation of Notch1-Stat3.
    Wu CX, Xu A, Zhang CC, Olson P, Chen L, Lee TK, Cheung TT, Lo CM, Wang XQ.
    Mol Cancer Ther; 2017 Aug 01; 16(8):1531-1543. PubMed ID: 28522590
    [Abstract] [Full Text] [Related]

  • 12. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
    De Keersmaecker K, Lahortiga I, Mentens N, Folens C, Van Neste L, Bekaert S, Vandenberghe P, Odero MD, Marynen P, Cools J.
    Haematologica; 2008 Apr 01; 93(4):533-42. PubMed ID: 18322257
    [Abstract] [Full Text] [Related]

  • 13. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers.
    Konishi J, Kawaguchi KS, Vo H, Haruki N, Gonzalez A, Carbone DP, Dang TP.
    Cancer Res; 2007 Sep 01; 67(17):8051-7. PubMed ID: 17804716
    [Abstract] [Full Text] [Related]

  • 14. Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014.
    Lanz TA, Wood KM, Richter KE, Nolan CE, Becker SL, Pozdnyakov N, Martin BA, Du P, Oborski CE, Wood DE, Brown TM, Finley JE, Sokolowski SA, Hicks CD, Coffman KJ, Geoghegan KF, Brodney MA, Liston D, Tate B.
    J Pharmacol Exp Ther; 2010 Jul 01; 334(1):269-77. PubMed ID: 20363853
    [Abstract] [Full Text] [Related]

  • 15. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.
    Yabuuchi S, Pai SG, Campbell NR, de Wilde RF, De Oliveira E, Korangath P, Streppel MM, Rasheed ZA, Hidalgo M, Maitra A, Rajeshkumar NV.
    Cancer Lett; 2013 Jul 10; 335(1):41-51. PubMed ID: 23402814
    [Abstract] [Full Text] [Related]

  • 16. Quantification of gamma-secretase modulation differentiates inhibitor compound selectivity between two substrates Notch and amyloid precursor protein.
    Yang T, Arslanova D, Gu Y, Augelli-Szafran C, Xia W.
    Mol Brain; 2008 Nov 04; 1():15. PubMed ID: 18983676
    [Abstract] [Full Text] [Related]

  • 17. HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro.
    Du Z, Li L, Sun W, Wang X, Zhang Y, Chen Z, Yuan M, Quan Z, Liu N, Hao Y, Li T, Wang J, Luo C, Wu X.
    Int J Oncol; 2018 Jul 04; 53(1):99-112. PubMed ID: 29658567
    [Abstract] [Full Text] [Related]

  • 18. Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia.
    Tammam J, Ware C, Efferson C, O'Neil J, Rao S, Qu X, Gorenstein J, Angagaw M, Kim H, Kenific C, Kunii K, Leach KJ, Nikov G, Zhao J, Dai X, Hardwick J, Scott M, Winter C, Bristow L, Elbi C, Reilly JF, Look T, Draetta G, Van der Ploeg L, Kohl NE, Strack PR, Majumder PK.
    Br J Pharmacol; 2009 Nov 04; 158(5):1183-95. PubMed ID: 19775282
    [Abstract] [Full Text] [Related]

  • 19. γ-Secretase inhibitors for breast cancer and hepatocellular carcinoma: From mechanism to treatment.
    Jia H, Wang Z, Zhang J, Feng F.
    Life Sci; 2021 Mar 01; 268():119007. PubMed ID: 33428878
    [Abstract] [Full Text] [Related]

  • 20. Down-regulation of Notch1 by gamma-secretase inhibition contributes to cell growth inhibition and apoptosis in ovarian cancer cells A2780.
    Wang M, Wu L, Wang L, Xin X.
    Biochem Biophys Res Commun; 2010 Feb 26; 393(1):144-9. PubMed ID: 20117093
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.